Free Trial
NASDAQ:CBUS

Cibus (CBUS) Stock Price, News & Analysis

Cibus logo
$1.13 +0.04 (+3.67%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$1.13 0.00 (0.00%)
As of 11/13/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cibus Stock (NASDAQ:CBUS)

Advanced

Key Stats

Today's Range
$1.02
▼
$1.14
50-Day Range
$1.09
▼
$1.71
52-Week Range
$1.02
▼
$4.19
Volume
148,182 shs
Average Volume
84,857 shs
Market Capitalization
$86.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00
Consensus Rating
Hold

Company Overview

Cibus is an agricultural technology company that develops plant traits using gene-editing technologies. Its proprietary Rapid Trait Development System (RTDS) is designed to make precise changes to a plant’s own genes, with the goal of developing useful crop characteristics without adding foreign DNA.

The company’s research and development focuses on traits for crops including canola, rice and wheat, such as herbicide tolerance and resistance to crop diseases. Cibus aims to bring these traits to market through seed and technology licensing arrangements with partners in the agricultural industry.

Cibus was formed in 2023 through a business combination involving Cibus Global and Calyxt, a plant-based gene-editing company. The company is headquartered in San Diego, California, and is led by co-founder Rory Riggs, who serves as its chairman and chief executive officer.

AI Generated. May Contain Errors.

Cibus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
31st Percentile Overall Score

CBUS MarketRank™: 
1.541298906595 of 5 stars

Cibus scored higher than 31% of companies evaluated by MarketBeat, and ranked 770th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cibus has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Cibus has a consensus price target of $9.00, representing about 696.5% upside from its current price of $1.13.

  • Amount of Analyst Coverage

    Cibus has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cibus' stock forecast and price target.
  • Earnings Growth

    Earnings for Cibus are expected to grow in the coming year, from ($1.13) to ($1.07) per share.

  • Price to Book Value per Share Ratio

    Cibus has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.75% of the float of Cibus has been sold short.
  • Short Interest Ratio / Days to Cover

    Cibus has a short interest ratio ("days to cover") of 61.82, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Cibus has recently decreased by 1.42%, indicating that investor sentiment is improving.
  • Dividend Yield

    Cibus does not currently pay a dividend.

  • Dividend Growth

    Cibus does not have a long track record of dividend growth.

  • News Sentiment

    Cibus has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Cibus this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Cibus insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    29.91% of the stock of Cibus is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    33.81% of the stock of Cibus is held by institutions.

  • Read more about Cibus' insider trading history.
Receive CBUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cibus and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CBUS Stock News Headlines

Cibus (CBUS) Q3 2026 Earnings Call Transcript
Cibus, Inc. (CBUS) Q3 2026 Earnings Call Transcript
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
Cibus Q3 2026 earnings preview
See More Headlines

CBUS Stock Analysis - Frequently Asked Questions

Cibus' stock was trading at $1.74 at the start of the year. Since then, CBUS shares have decreased by 35.1% and is now trading at $1.13.

Cibus, Inc. (NASDAQ:CBUS) announced its quarterly earnings results on Thursday, November, 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by $0.09. The business earned $800 thousand during the quarter, compared to the consensus estimate of $1.30 million. Cibus had a negative net margin of 2,131.38% and a negative trailing twelve-month return on equity of 526.66%.
Read the conference call transcript
.

Cibus (CBUS) raised $63 million in an initial public offering on Thursday, July 20th 2017. The company issued 7,000,000 shares at $8.00-$10.00 per share. Morgan Stanley, BofA Merrill Lynch and Piper Jaffray served as the underwriters for the IPO.

Cibus' top institutional investors include State Street Corp (0.21%), Capital Advisor Network LLC (0.12%), Prescott Group Capital Management L.L.C. (0.11%) and StoneX Group Inc. (0.04%). Insiders that own company stock include Gregory Francis William Gocal, Noel Sauer, Carlo Broos and Gerhard Prante.
View institutional ownership trends
.

Shares of CBUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cibus investors own include Applied Digital (APLD), NVIDIA (NVDA), Archer Aviation (ACHR), Pfizer (PFE), Applied Optoelectronics (AAOI), Arcutis Biotherapeutics (ARQT) and Coinbase Global (COIN).

Company Calendar

Last Earnings
11/12/2026
Today
11/15/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBUS
Previous Symbol
NASDAQ:CBUS
CIK
1705843
Fax
N/A
Employees
118
Year Founded
2001

Price Target and Rating

High Price Target
$15.00
Low Price Target
$3.00
Potential Upside/Downside
+696.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.50)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.08 million
Net Margins
-2,131.38%
Pretax Margin
-2,145.48%
Return on Equity
-526.66%
Return on Assets
-28.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.95
Quick Ratio
0.95

Sales & Book Value

Annual Sales
$3.64 million
Price / Sales
23.73
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.40 per share
Price / Book
2.83

Miscellaneous

Outstanding Shares
76,430,000
Free Float
53,569,000
Market Cap
$86.37 million
Optionable
Optionable
Beta
1.65

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:CBUS) was last updated on 11/13/2026 by MarketBeat.com Staff.
From Our Partners